News und Analysen
EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
At a meeting with the investment community today, Pfizer Inc. (NYSE: PFE) outlined its strategic priorities for the newly formed Oncology organization — and how its deep and diverse pipeline
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons
EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
EQS-Adhoc: BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the
Agilent Presents Solutions Innovation Research Awards to Drexel University and Prairie View A&M University Researchers
Agilent Technologies Inc. (NYSE: A) today announced the selection of Distinguished Professors Michel Barsoum and Yury Gogotsi at Drexel University and Professor Ananda Amarasekara at Prairie View
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program
EQS-News: MEDICLIN presents preliminary figures for the 2023 financial year
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45th Annual Institutional Investors Conference, which is being held March 3 - 6
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: 3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an